BioAtlaBCAB
BCAB
About: BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Employees: 65
0
Funds holding %
of 6,794 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
26% more call options, than puts
Call options by funds: $83K | Put options by funds: $66K
8% less capital invested
Capital invested by funds: $32.9M [Q2] → $30.4M (-$2.57M) [Q3]
14.06% less ownership
Funds ownership: 49.83% [Q2] → 35.77% (-14.06%) [Q3]
20% less funds holding
Funds holding: 79 [Q2] → 63 (-16) [Q3]
55% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 29
67% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 27
100% less funds holding in top 10
Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$5
205%
upside
Avg. target
$5
205%
upside
High target
$5
205%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Reni Benjamin 33% 1-year accuracy 7 / 21 met price target | 205%upside $5 | Market Outperform Reiterated | 16 Sept 2024 |
Financial journalist opinion
Neutral
Finbold
3 weeks ago
‘Big Short' Michael Burry stock portfolio update
After the famous ‘Big Short' investor Michael Burry abandoned his 2023 bet against the semiconductor industry – though, interestingly, the short position may not have been wrong, only poorly timed – he again stirred controversy with his persistent bullishness about Chinese stocks.
Neutral
Seeking Alpha
4 weeks ago
BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Conference Call Participants Jeet Mukherjee - BTIG Tony Butler - Rodman & Renshaw Yu He - H.C. Wainwright Operator Good day, everyone, and welcome to today's BioAtla Third Quarter 2024 Earnings Call.
Neutral
Seeking Alpha
2 months ago
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy
BioAtla's proprietary CAB platform offers precise cancer targeting, minimizing harm to healthy cells, with promising clinical trial outcomes for its ADCs and immuno-oncology treatments. The company faces a tight cash runway until Q3 2025, raising concerns about dilution and short-term stock headwinds. Ozuriftamab Vedotin shows promising Phase 2 results and received FDA Fast Track Designation, enhancing its potential.
Positive
Seeking Alpha
2 months ago
BioAtla: Numerous Catalysts Coming In Q4
BioAtla, Inc. has promising pipeline projects, including masked antibodies and ADCs targeting AXL and ROR2, showing early efficacy and potential for improved cancer treatments. Financially, BioAtla faces challenges with less than a year of cash, despite a licensing deal with Context Therapeutics providing some runway extension. The company's cash position poses a significant risk, necessitating future fundraising, and potentially leading to substantial dilution and market volatility.
Neutral
GlobeNewsWire
2 months ago
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.
Negative
Finbold
2 months ago
Michael Burry buys 634,000 shares of this $1 penny stock
When Michael Burry, the man who famously bet against the housing market before the 2008 financial crash, makes a move, investors take notice.
Neutral
GlobeNewsWire
2 months ago
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced acceptance of an abstract for oral presentation at the upcoming Society for Melanoma Research 21st International Congress (SMR), being held from October 10–13, 2024, in New Orleans, LA.
Neutral
GlobeNewsWire
2 months ago
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales Context anticipated IND filing for BA3362 in mid-2026 SAN DIEGO and PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (“BioAtla”) (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (“CAB”) antibody therapeutics for the treatment of solid tumors, and Context Therapeutics Inc. (“Context”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the companies have entered into an agreement under which Context has obtained from BioAtla an exclusive, worldwide license to develop, manufacture and commercialize BA3362, BioAtla's Nectin-4 x CD3 TCE.
Neutral
Seeking Alpha
3 months ago
BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Dr. Jay Short - Chairman, Co-Founder and CEO Richard Waldron - Chief Financial Officer Dr. Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Brian Cheng - JPMorgan Arthur He - H.C. Wainwright Operator Good day, everyone.
Neutral
GlobeNewsWire
4 months ago
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today hosted a virtual R&D Day on its novel conditionally and reversibly active antibody drug conjugate mecbotamab vedotin, targeting the receptor tyrosine kinase AXL, and its antibody targeting CTLA-4, evalstotug. The R&D Day also featured renowned key opinion leaders, Dr. Edwin Yau, Dr. Omid Hamid and Dr. Ankit Mangla.
Charts implemented using Lightweight Charts™